Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan for Prevention of DCI in aSAH (REACT)
NCT03585270Phase 3Completed
- Sponsor
- Idorsia
- Start
- Feb 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in aneurysmal subarachnoid hemorrhage (SAH) comparing Clazosentan Arm with Placebo Arm (2 arms). Primary endpoint: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days. Started Feb 2019; status: completed.
02
Drugs
clazosentan
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT03585270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585270.